#AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show

#AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show

Publication date: May 13, 2019

This post was originally published on this site Aubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, a pooled analysis of Phase 2 and Phase 3 trial results show. These studies enrolled relapsing MS patients, categorized into subgroups depending on whether they had a prior treatment (and type of treatment): those who were treatment-nacEFve (no treatment for two years before joining the trial); those recently treated with Aubagio at 7 mg (core studies started some patients at 7 mg before moving them to 14 mg in extension trials); and those recently treated with another disease-modifying therapy (DMT), further subdivided into patients who discontinued that DMT within 6 months prior to enrolling in an Aubagio study, and those who stopped using a different DMT between six months and two years before. In this pooled post-hoc analysis of all Aubagio trials, researchers evaluated the long-term efficacy and safety of its use in patients categorized by type of prior MS treatment (including those who were using no treatment in the two years prior to an Aubagio study’s start and were classified as treatment naive). The pooled analysis included 1,695 patients treated with Aubagio at 14 mg daily, of whom 1,021 had been treatment nacEFve, 353 had taken Aubagio at 7 mg, 158 had used another DMT within six months of a study’s start (called a baseline measure), and 163 patients who had stopped another DMT in the longer time group. These findings show that Aubagio at 14 mg effectively lowers disability in the long-term in relapsing MS patients, irrespective of their prior treatment preferences, the researchers concluded.

Concepts Keywords
Biogen Medicine
Clinical Trials Health
Copaxone Immunosuppressants
Diarrhea Clinical medicine
Disability Clinical research
DMT Multiple sclerosis
European Commission Natalizumab
FDA Clinical trial
Fingolimod Teriflunomide
Genzyme Placebo
Gilenya Nausea
Glatiramer Acetate Switch treatments disease
Incidence Disease
Interferon Beta Lower
Liver Control placebo
Milligram Respective groups
Multiple Sclerosis
Natalizumab
Nausea
Neurology
Placebo
Post Hoc
Relapse
Sequencing
Stony Brook
Subgroup
Teva
Thinning
Tysabri

Semantics

Type Source Name
drug DRUGBANK Fingolimod
gene UNIPROT DMTN
disease MESH disease progression
gene UNIPROT SLC35G1
disease MESH relapse
disease MESH multiple sclerosis
disease DOID multiple sclerosis
drug DRUGBANK Teriflunomide
drug DRUGBANK Antithymocyte immunoglobulin (rabbit)
drug DRUGBANK Glatiramer
drug DRUGBANK Natalizumab
gene UNIPROT SMIM10L2B
gene UNIPROT SMIM10L2A
disease DOID diarrhea
pathway BSID Release
drug DRUGBANK Nonoxynol-9

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *